Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $1.90B.
ENTERPRISE VALUE (EV)
$1.90B
Viridian Therapeutics, Inc.
Market Cap
$2.06B
Enterprise Value (EV)
$1.90B
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Viridian Therapeutics, Inc. (VRDN) | $2.06B | $1.90B |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | $2.02B |
| Alvotech (ALVO)vs › | $2.08B | $3.39B |
| Vericel Corporation (VCEL)vs › | $2.05B | $2.02B |
| Progyny, Inc. (PGNY)vs › | $2.03B | $1.90B |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | $2.28B |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | $1.97B |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | $2.14B |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | $1.90B |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | $2.14B |
Market Cap
$2.06B
Total Debt
$49.94M
Cash
$212.38M
Enterprise Value
$1.90B
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
